The EHMT2 Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for the disruption of the EHMT2 gene in the LoVo human colorectal adenocarcinoma cell line. This gene-edited product serves as a loss-of-function model to investigate the epigenetic functions and oncogenic roles of EHMT2, a histone methyltransferase responsible for H3K9me1/2 deposition and transcriptional repression. The polyclonal nature of this knockout pool preserves the heterogeneity of the edited population, making it suitable for studies that do not require monoclonal isolation but benefit from a population-wide gene disruption phenotype. The knockout was generated using CRISPR/Cas9-mediated gene disruption, targeting the EHMT2 locus to ablate its methyltransferase activity, thereby relieving the repression of downstream tumor suppressor genes.
The LoVo parental cell line was originally established from a metastatic lymph node of a patient with colon adenocarcinoma and exhibits an adherent epithelial morphology. These cells are widely employed as a model system for metastatic colorectal carcinoma, displaying aggressive growth characteristics and invasive potential. LoVo cells harbor mutations in key oncogenic pathways, including APC, KRAS, and TP53, which contribute to their tumorigenic and metastatic properties. Their well-characterized genetic background and responsiveness to chemotherapeutic agents make them an ideal host for studying epigenetic mechanisms in colorectal cancer progression. By engineering EHMT2 knockout in LoVo cells, researchers can examine how loss of this histone methyltransferase modulates the metastatic and proliferative capacities inherent to this cell line.
EHMT2 (also known as G9a) is a histone methyltransferase that forms a complex with EHMT1/GLP to catalyze mono- and di-methylation of histone H3 at lysine 9 (H3K9me1/2), marks associated with chromatin compaction and gene silencing. It is regulated by upstream factors such as MYC, E2F1, ??-catenin/TCF, TGF-??, and HIF-1??, and is post-transcriptionally modulated by microRNAs like miR-217 and miR-137. EHMT2-mediated H3K9me2 recruits HP1?? and DNMTs, leading to stable transcriptional repression of tumor suppressor genes including CDH1 (E-cadherin), p16/INK4a, p21/WAF1, DLC1, and RUNX3. Additionally, EHMT2 interacts with transcriptional repressors such as E2F6, CtBP, and REST, further reinforcing gene silencing networks. Disruption of EHMT2 is therefore expected to alleviate repression at these loci, reactivating cellular pathways linked to cell adhesion, cell cycle arrest, and apoptosis.
In the context of LoVo colorectal cancer cells, EHMT2 knockout provides a powerful tool to dissect the epigenetic silencing mechanisms that drive metastatic behavior and therapy resistance. LoVo cells rely on EHMT2 activity to maintain H3K9me2 levels at promoters of genes like CDH1, whose loss is critical for epithelial-mesenchymal transition (EMT) and invasion. Abrogation of EHMT2 in this model may restore E-cadherin expression, diminishing invasive capacity, and can upregulate cell cycle inhibitors such as p16, leading to growth suppression. Furthermore, this knockout system enables the investigation of crosstalk between EHMT2 and key colorectal cancer pathways, including Wnt/??-catenin and TGF-?? signaling, where EHMT2 cooperates with ??-catenin/TCF to repress target genes. The polyclonal population approach captures a range of editing outcomes, reflecting a more physiologically relevant mix of knockdown efficiencies that can be correlated with functional readouts.
This EHMT2 knockout cell product is optimally suited for a broad spectrum of research applications, including the screening of small-molecule EHMT2 inhibitors, the study of epigenetic reactivation of silenced tumor suppressors, and the global analysis of histone modification changes via ChIP-seq or ChIP-qPCR for H3K9me2. Researchers can employ this model in proliferation, colony formation, migration, and invasion assays to assess phenotypic consequences, or in RNA-seq experiments to identify transcriptome-wide alterations upon EHMT2 disruption. Additional uses include drug sensitivity testing to explore synthetic lethal interactions and immunofluorescence or flow cytometry to monitor protein re-expression. For further details on product specifications, validation data, and purchasing options, please contact Ascent Research.
